Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX208 plus trametinib in advanced solid tumors
CTR20220338Phase 2Active
- Sponsor
- HyBioPharma
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HLX208, trametinib in Nonhematologic neoplasms, colorectal cancer (CRC), non-small cell lung cancer (NSCLC), primary brain neoplasm, sponsored by HyBioPharma. Started Jan 2022; status: active.
02
Drugs
HLX208trametinib
03
Conditions
Nonhematologic neoplasmscolorectal cancer (CRC)non-small cell lung cancer (NSCLC)primary brain neoplasm
Beyond the preview
Go deeper on CTR20220338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220338.